奥拉帕利联合用药治疗上皮性卵巢癌的研究进展  

Combination Drug Therapy with Olaparib in Epithelial Ovarian Cancer:an Overview

作　　者：朱忆晨 杨天 王运发 谭布珍[1] ZHU Yi-chen;YANG Tian;WANG Yun-fa;TAN Bu-zhen(Department of Obstetrics and Gynecology,the Second Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院妇产科,南昌330006

出　　处：《南昌大学学报（医学版）》2024年第6期92-96,共5页Journal of Nanchang University：Medical Sciences

基　　金：国家自然科学基金资助项目(82160766)。

摘　　要：奥拉帕利(Olaparib)作为首个针对卵巢癌开发的聚腺苷二磷酸核糖聚合酶(PARP)抑制剂,已被广泛用于上皮性卵巢癌的维持治疗,显著延长了患者的生存期。然而仍有部分患者单药疗效欠佳或出现逐步耐药。将奥拉帕利与血管内皮生长因子(VEGF)抑制剂、酪氨酸激酶抑制剂(TKI)、免疫检查点抑制剂(ICI)、化疗药物以及ATR抑制剂等药物联用,可通过药物间的协同作用,延缓或克服上皮性卵巢癌患者对治疗的耐药性,并增强患者对药物的敏感性。联合治疗的策略能够改善这类患者的预后,特别是在携带BRCA基因突变的患者群体中,其疗效更为显著,但安全性及长期有效性仍有待更大规模临床试验加以论证。Olaparib,the first polyadenosine diphosphate-ribose polymerase(PARP)inhibitor developed for ovarian cancer,has been widely used as a maintenance therapy for epithelial ovarian cancer,significantly prolonging patient survival.However,some patients still experience poor single-agent efficacy or progressive drug resistance.The combination of olaparib with drugs such as vascular endothelial growth factor(VEGF)inhibitors,tyrosine kinase inhibitors(TKIs),immune checkpoint inhibitors(ICIs),chemotherapy agents,and ATR inhibitors can delay or overcome treatment resistance and enhance drug sensitivity through synergistic effects between drugs in patients with epithelial ovarian cancer.The combination drug therapy with olaparib for epithelial ovarian cancer can positively improve prognosis,particularly in the population of patients carrying BRCA gene mutations,where its efficacy is more significant.However,the safety and long-term effectiveness still need to be demonstrated through larger-scale clinical trials.

关 键 词：上皮性卵巢癌 PARP抑制剂 联合用药 协同效应 

分 类 号：R737.31[医药卫生—肿瘤]